一则大消息，罕见暴涨超24%

Group 1 - Heng Rui Pharmaceutical experienced a significant stock surge of 24.54%, closing at HKD 84.75 per share, following an announcement of a licensing agreement with GlaxoSmithKline (GSK) [11] - The agreement grants GSK global exclusive rights to the HRS-9821 project and options for up to 11 additional projects, excluding certain regions in China [11] - GSK will pay Heng Rui Pharmaceutical an upfront fee of USD 500 million, with potential milestone payments totaling up to USD 12 billion if all projects are successfully developed and commercialized [11] Group 2 - The Hong Kong stock market showed mixed results, with the Hang Seng Index rising by 0.68% to 25,562.13 points, while the Hang Seng Technology Index fell by 0.24% [2][3] - The overall market turnover reached HKD 250.3 billion, with net inflows from southbound trading amounting to HKD 9.25 billion [2] - Pharmaceutical stocks performed strongly, with the oncology index leading gains at 9.17% and the innovative drug index rising by 7.5% [3]